Delighted to welcome Robert Evans as the new chief executive of Wellcome Genome Campus, joining the leadership team alongside Phil Clark, Colette O'Shea and Matt Green. https://lnkd.in/eF-YJZxa [wellcome.org]
Wellcome Genome Campus
Wellness and Fitness Services
Hinxton, Cambridgeshire 11,270 followers
Home to some of the world's foremost institutions and companies in genomics and biodata revolutionizing human healthcare
About us
The Wellcome Genome Campus is home to some of the world's foremost institutes and organisations in genomics and computational biology, committed to delivering life-changing science with the reach, scale, and imagination to solve some of humanity's greatest challenges. The Campus is part of Wellcome, a global charitable foundation that exists to improve health for everyone by helping great ideas to thrive housing the Wellcome Trust Sanger Institute (WTSI), the European Bioinformatics Institute (EBI) the bioinformatics outstation of the European Molecular Biology Laboratory (EMBL), the Biodata Innovation Centre, Connecting Science,Genomics England. and a number of biotech companies whose UK offices are located in the Biodata Innovation Centre acting as an incubator for businesses of all sizes. Here on Campus we carry out genome and biodata research and provide bioinformatics resources for the global scientific community. We also deliver vital training in genomics and biodata to scientists and clinicians working at the interface of research and industry, translating science into tangible societal benefits. Covering a wide variety of products, tools, and technologies, the Wellcome Genome Campus supports globally important partnerships and projects in genomics and computational biology. For more information about the companies moving in to take office space at this growing hub for genomic research and to get in touch, please visit our website.
- Website
-
http://www.wellcomegenomecampus.org
External link for Wellcome Genome Campus
- Industry
- Wellness and Fitness Services
- Company size
- 1,001-5,000 employees
- Headquarters
- Hinxton, Cambridgeshire
- Type
- Nonprofit
- Founded
- 1994
- Specialties
- Biomedical research, Genome and biodata research, Bioinformatics, Medical research, genomics, scientific entrepreneurship, and industry
Locations
-
Primary
Get directions
Wellcome Genome Campus
Hinxton, Cambridgeshire CB10 1SA, GB
Employees at Wellcome Genome Campus
-
Richard Milne
Deputy Director, Kavli Centre for Ethics, Science, and the Public, University of Cambridge; Head of Research and Dialogue at Wellcome Connecting…
-
Marla D. Baldwin
Separation and Transformation | Operating Model Change | Private Equity | ex-KKR Portfolio & Big 4
-
Matt Green
Interim CFO, Wellcome Genome Campus
-
Ceri Harrop
Freelance Public Engagement Professional / Trainer
Updates
-
Wellcome Genome Campus reposted this
Introducing the #Target2Patient 2024 keynote speakers: 🗣️Dr Melanie Lee, CEO at Think 10 a life science business consultancy, Formerly CEO at LifeArc 🗣️Professor Sir Munir Pirmohamed, NHS Chair of Pharmacogenetics, University of Liverpool, Director of the Wolfson Centre for Personalised Medicine and MRC Centre for Drug Safety Sciences, Commissioner on Human Medicines (CHM) Early bird registration deadline EXTENDED until 1 March, register before midnight to receive a discount: https://lnkd.in/eSQJ84xX Join the conversation on how advances in #genomics for target choice, #invitro technologies, #novelmodalities, #AIML, and #digitalhealth can radically increase the discovery of disease relevant biological targets and the development of new drugs. 📆 29–30 April 2024 📍 Hinxton Hall Conference Centre, Wellcome Genome Campus, Cambridgeshire, UK, or online via our dedicated conference web portal Participate in live Q&A and panel discussion sessions, take advantage of networking opportunities, poster sessions, vendor exhibitions and on-demand materials. Supported by: ELRIG UK, Society for Medicines Research Our sponsors: European Bioinformatics Institute | EMBL-EBI, GSK, AstraZeneca #drugdiscovery #genomics #drugtargets #clinicaltrialsdesign #digitalhealth #personalisedmedicine #pharmacogenetics #biotechnology Ian Gilmore Mike Hann Andrew Leach Samantha Peel Claire Steppan National Physical Laboratory (NPL) Imperial College London British Pharmacological Society David Hulcoop Marcus Bantscheff Fabian Theis Lorna Ewart Tony Ng Martin Knight Emanuela Cuomo Matthias Brand Paul McInulty Jack Scannell Alexander Schuhmacher Laura Williams Chris de Graaf Nicola Richmond
-
Wellcome Genome Campus reposted this
Register for our webinar! Advances in genome editing tools are expanding development of new and innovative cell and gene therapies. However, progress through to clinic requires stringent pre-clinical assessments of all off-target #geneediting events to ensure safe and efficacious use in patients. Join our webinar where our CEO, Felix Dobbs, will be sharing an educational session outlining how our cutting-edge INDUCE-seq™ platform is enabling researchers to measure and quantify the specificity of off-target genetic edits and evaluate the associated genetic outcomes. 📆 29 Feb 🕑5pm GMT #CRISPR #Celltherapy #Genetherapy Want to learn more? Reserve your free spot here: https://lnkd.in/d9RCf2GX
-
-
Wellcome Genome Campus reposted this
Broken String Biosciences has today announced that the Company's INDUCE-seq DNA break mapping platform has been used to demonstrate the impact of structural DNA changes on specificity of #CRISPR-Cas9 #geneediting, in new #research published in Molecular Cell. As part of the study, the team analysed the impact of alterations to DNA structure, in the form of negative supercoiling, on off-target effects of Cas9. Using INDUCE-seq, the team confirmed that gene edited cells exhibited up to 10,000 genome-wide off-target events, formed as a result of increased mismatch tolerance. Find out more here: https://rb.gy/wetb3
-
-
Wellcome Genome Campus reposted this
Mosaic Therapeutics has been shortlisted for the Series A Finance Raise of the Year in the European #LifeStarsAwards 🌟 Testament to our team and unique approach, we closed our Series A funding round earlier this year to advance our preclinical pipeline of targeted oncology therapeutics, developed in biomarker-defined settings to provide safer, more effective medicines for patients. Thank you, LSX - partnering for Life Science eXecutives, and best of luck to the other nominees! #DrugDiscovery #DrugDevelopment #Oncology
-